Do we need to redefine the advanced stage in Parkinson's disease?

被引:0
|
作者
Sesar, Angel [1 ]
Fernandez-Pajarin, Gustavo [1 ]
Ares, Begona [1 ]
Castro, Alfonso [1 ]
机构
[1] Hosp Clin Univ, Movement Disorder Unit, Neurol Dept, Santiago De Compostela, Spain
来源
REVISTA MEXICANA DE NEUROCIENCIA | 2021年 / 22卷 / 04期
关键词
Parkinson's disease; Advanced stage; Post-advanced stage; Dopaminergic symptoms; Non-dopaminergic symptoms; SYDNEY MULTICENTER; SYMPTOMS;
D O I
10.24875/RMN.20000119
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Identifying the advanced stage in Parkinson's disease ( PD) is crucial for shifting from conventional to device-aided therapies. The criteria to define the onset of advanced PD have been based on lengthy and disabling daily off-times, troublesome dyskinesia and complex therapeutic regimes, but have also included invalidating non-dopaminergic symptoms, such as dementia, falls or dysphagia. These last problems usually appear in a much later stage of the advanced PD. The key to the definition of advanced PD should be the lack of adequate PD control of both motor and non-motor dopaminergic symptoms. The patient's judgment about the quality of their response to conventional therapy is also critical to establish the advanced stage. The early identification of this phase allows maintaining the patient's functional state whenever appropriate treatments are applied. We should keep the term advanced stage when the dopaminergic symptoms responsive to device-aided therapy are preponderant. When invalidating non-dopaminergic symptoms dominate the clinical picture, the term post-advanced stage could be more suitable.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 50 条
  • [31] Progress in Parkinson's disease - Where do we stand?
    Toulouse, Andre
    Sullivan, Aideen M.
    PROGRESS IN NEUROBIOLOGY, 2008, 85 (04) : 376 - 392
  • [32] How do we slow progression of Parkinson's disease
    Kieburtz, K.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S12 - S12
  • [33] Why do we need outcomes research in end stage renal disease?
    Nicolucci, A
    Procaccini, DA
    JOURNAL OF NEPHROLOGY, 2000, 13 (06) : 401 - 404
  • [34] Preoperative Chemotherapy for Breast Cancer: Do We Need to Redefine Our End Points?
    Tara M. Breslin
    Annals of Surgical Oncology, 2003, 10 : 716 - 717
  • [35] Body composition in advanced-stage Parkinson’s disease
    M. L. Petroni
    G. Albani
    V. Bicchiega
    S. Baudo
    C. Vinci
    A. Montesano
    G. Izzo
    P. Bertocco
    S. Mazzotta
    E. Zorzetto
    F. Balzola
    A. Mauro
    Acta Diabetologica, 2003, 40 : s187 - s190
  • [36] Body composition in advanced-stage Parkinson's disease
    Petroni, ML
    Albani, G
    Bicchiega, V
    Baudo, S
    Vinci, C
    Montesano, A
    Izzo, G
    Bertocco, P
    Mazzotta, S
    Zorzetto, E
    Balzola, F
    Mauro, A
    ACTA DIABETOLOGICA, 2003, 40 (Suppl 1) : S187 - S190
  • [37] A case of splenic lymphangioendotheliomatosis: Do we need to redefine the Kasabach-Merritt phenomenon?
    Carlo-Demovich, Jamie
    Caplan, Michael
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (04) : 649 - 649
  • [38] Complications of Parkinson's disease treatment. How do we manage psychosis in Parkinson's disease?
    Manuel Garcia-Moreno, Jose
    REVISTA DE NEUROLOGIA, 2010, 50 : S51 - S51
  • [39] Do we need to redefine post-partum hemorrhage for our modern population?
    Conner, Shayna
    Tuuli, Methodius
    Colvin, Ryan
    Odibo, Anthony
    Macones, George
    Cahill, Alison
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (01) : S206 - S206
  • [40] Treatment complications in Parkinson's disease. How do we manage depression in Parkinson's disease?
    Balaguer-Martinez, Ernest
    REVISTA DE NEUROLOGIA, 2010, 50 : S45 - S47